跳至主要内容
临床试验/NCT01162967
NCT01162967已完成2 期

PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE

Hospital Universitari Vall d'Hebron Research Institute3 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
78
试验地点
3
主要终点
Parasitological cure measured by a real time PCR in blood sample

研究概览

简要总结

The investigators propose the evaluation of posaconazole and benznidazole in humans for the treatment of Chagas disease chronical infection. Exploratory trial of posaconazole antiparasitic activity against Trypanosoma cruzi.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consenting patients with serological evidence of Chagas infection and positive PCR real time

排除标准

  • 未提供

研究组 & 干预措施

Benznidazole

Active Comparator

干预措施: Benznidazole (Drug)

Posaconazole, low dose

Experimental

干预措施: Posaconazole (Drug)

Posaconazole, high dose

Experimental

干预措施: Posaconazole (Drug)

结局指标

主要结局

Parasitological cure measured by a real time PCR in blood sample

时间窗: 12 months after starting treatment

PCR negative at the end of follow up

次要结局

  • Parasitological cure measured by real time PCR in blood sample(End of treatment, weeks 8, 16, 24 and 40 after treatment)
  • Safety and tolerability of both drugs(First 2 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验